All articles by Annabel Kartal Allen

Annabel Kartal Allen

Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel

Clariyon’s AI tool boosts sepsis care compliance in hospital study

Clariyon’s artificial intelligence (AI)-powered sepsis care agent has shown potential in improving a physician’s ability to provide quality care to…
Advanced Medical Solutions mulls £715m HB Fuller takeover bid

Adhesives manufacturing giant, HB Fuller, has put £715m ($942.5m) on the table to acquire wound care specialist Advanced Medical Solutions…
BrightHeart secures CE mark for AI-powered prenatal ultrasound platform

Parisian medtech company, BrightHeart, has obtained a CE mark for its artificial intelligence (AI)-based tool to optimise the prenatal ultrasound…
Tissium wins €60m to bring sutureless nerve repair system to market

Following the US Food and Drug Administration’s (FDA) decision to award a De Novo authorisation to Tissium’s sutureless nerve repair…
PorTal Access secures FDA clearance for vascular access ports

The US Food and Drug Administration (FDA) has granted Miami-based medical device specialist, PorTal Access clearance for its range of…

HLTH Europe 2026: enriching the patient journey with health technologies

With the pharma, biotech and medtech sectors debuting new and potentially life-changing innovations for patients at a rapid pace, many…
FDA oncology roundup: drugs, imaging agents and diagnostics gain approval

Over the last few days, the US Food and Drug Administration (FDA) has granted approval to several oncology products across…
Women’s health apps: governance and transparency key to success as opportunities bloom

As the use of digital health apps continues to surge across both the specialist health and general wellness spaces, so…
Abbott obtains CE mark for duo of glucose-ketone monitors

Medtech giant Abbott has secured a CE mark for two of its glucose-ketone sensing systems for diabetic patients, making the…
Rivermark pockets $20m in Series D for late-stage prostate device trial

Wisconsin-based medtech Rivermark Medical has secured $20m in a Series D financing round – supporting the company’s late-stage clinical activities…